162 related articles for article (PubMed ID: 16314741)
21. First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07).
von Moos R; Seifert B; Simcock M; Goldinger SM; Gillessen S; Ochsenbein A; Michielin O; Cathomas R; Schläppi M; Moch H; Schraml PH; Mjhic-Probst D; Mamot C; Schönewolf N; Dummer R;
Ann Oncol; 2012 Feb; 23(2):531-6. PubMed ID: 21527587
[TBL] [Abstract][Full Text] [Related]
22. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
[TBL] [Abstract][Full Text] [Related]
23. Temozolomide in combination with interferon alpha-2b in patients with metastatic melanoma: a phase I dose-escalation study.
Agarwala SS; Kirkwood JM
Cancer; 2003 Jan; 97(1):121-7. PubMed ID: 12491513
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.
Plummer R; Lorigan P; Steven N; Scott L; Middleton MR; Wilson RH; Mulligan E; Curtin N; Wang D; Dewji R; Abbattista A; Gallo J; Calvert H
Cancer Chemother Pharmacol; 2013 May; 71(5):1191-9. PubMed ID: 23423489
[TBL] [Abstract][Full Text] [Related]
25. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
[TBL] [Abstract][Full Text] [Related]
26. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma.
Lian B; Si L; Cui C; Chi Z; Sheng X; Mao L; Li S; Kong Y; Tang B; Guo J
Clin Cancer Res; 2013 Aug; 19(16):4488-98. PubMed ID: 23833309
[TBL] [Abstract][Full Text] [Related]
27. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Chiarion-Sileni V; Guida M; Ridolfi L; Romanini A; Del Bianco P; Pigozzo J; Brugnara S; Colucci G; Ridolfi R; De Salvo GL;
Br J Cancer; 2011 Jun; 104(12):1816-21. PubMed ID: 21610711
[TBL] [Abstract][Full Text] [Related]
28. Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Clark JI; Moon J; Hutchins LF; Sosman JA; Kast WM; Da Silva DM; Liu PY; Thompson JA; Flaherty LE; Sondak VK
Cancer; 2010 Jan; 116(2):424-31. PubMed ID: 19918923
[TBL] [Abstract][Full Text] [Related]
29. Multi-institutional phase II randomized trial of integrated therapy with cisplatin, dacarbazine, vindesine, subcutaneous interleukin-2, interferon alpha2a and tamoxifen in metastatic melanoma. BREMIM (Biological Response Modifiers in Melanoma).
Sertoli MR; Queirolo P; Bajetta E; Del Vecchio M; Comella G; Barduagni L; Bernengo MG; Vecchio S; Criscuolo D; Bufalino R; Morabito A; Cascinelli N
Melanoma Res; 1999 Oct; 9(5):503-9. PubMed ID: 10596917
[TBL] [Abstract][Full Text] [Related]
30. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
[TBL] [Abstract][Full Text] [Related]
31. A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma.
Patel SP; Kim DW; Bassett RL; Cain S; Washington E; Hwu WJ; Kim KB; Papadopoulos NE; Homsi J; Hwu P; Bedikian AY
Cancer Immunol Immunother; 2017 Oct; 66(10):1359-1366. PubMed ID: 28612140
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.
McQuade JL; Posada LP; Lecagoonporn S; Cain S; Bassett RL; Patel SP; Hwu WJ; Hwu P; Davies MA; Bedikian AY; Amaria RN
Melanoma Res; 2016 Dec; 26(6):604-608. PubMed ID: 27540836
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Laber DA; Okeke RI; Arce-Lara C; Taft BS; Schonard CL; McMasters KM; Kloecker GH; Miller DM
J Cancer Res Clin Oncol; 2006 Sep; 132(9):611-6. PubMed ID: 16741726
[TBL] [Abstract][Full Text] [Related]
34. Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
Xia C; Leon-Ferre R; Laux D; Deutsch J; Smith BJ; Frees M; Milhem M
Cancer Chemother Pharmacol; 2014 Oct; 74(4):691-7. PubMed ID: 25062770
[TBL] [Abstract][Full Text] [Related]
35. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775.
Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN
Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
[TBL] [Abstract][Full Text] [Related]
37. The clinical efficacy of combination of docetaxel and temozolomide in previously treated patients with stage IV melanoma.
Yoon C; Papadopoulos NE; Camacho LH; McIntyre S; Alvarado GC; Bedikian AY; Hwu P; Kim KB
Melanoma Res; 2010 Feb; 20(1):43-7. PubMed ID: 19952963
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of biochemotherapy with interferon alpha, dacarbazine, cisplatin and tamoxifen in metastatic melanoma: a Southwest Oncology Group trial.
Margolin KA; Liu PY; Unger JM; Fletcher WS; Flaherty LE; Urba WJ; Hersh EM; Hutchins LE; Sosman JA; Smith JW; Weiss GR; Sondak VK
J Cancer Res Clin Oncol; 1999; 125(5):292-6. PubMed ID: 10359134
[TBL] [Abstract][Full Text] [Related]
39. A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma.
Larkin JM; Hughes SA; Beirne DA; Patel PM; Gibbens IM; Bate SC; Thomas K; Eisen TG; Gore ME
Br J Cancer; 2007 Jan; 96(1):44-8. PubMed ID: 17146474
[TBL] [Abstract][Full Text] [Related]
40. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
